Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000364

Drug Information
NameIrbesartan
SynonymsAC-537; BMS-186295, SR-47436, Aprovel, Karvea, Irbesartan; MolPort-003-666-550; Aprovel; Karvea; KBio2_002231; Irbesarran; Avapro (TN); SPECTRUM1504259; DB01029; HMS2051L08; Spectrum3_000994; I06-0690; UNII-J0E2756Z7N; MLS001424099; S1507_Selleck; 2-butyl-3-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one; Lrbesartan; 2-butyl-3-[ p -( o -1 H -tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4,4]non-1-en-4-one; 1,3-Diazaspiro(4.4)non-1-en-4-one, 2-butyl-3-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-; Avapro; Spectrum_001751; 2-Butyl-3-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-1,3-diazaspiro(4.4)non-1-en-4-one; Bristol Myers Brand of Irbesartan; KBioSS_002231; Jsp002315; AC1L1GMK; Spectrum5_001288; Bio-0053; CHEBI:5959; 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-butyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-; Sanofi Winthrop Brand of Irbesartan; 2-Butyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[4.4]non-1-en-4-one; CID3749; C25H28N6O; 2-butyl-3-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[; SAM001246548; HMS2093E16; BSPBio_002687; KBio2_007367; BRD-K60038276-001-02-5; SPBio_001889; SR-47436; NCGC00095122-02; L000319; NCGC00095122-01; Irbesartan (JAN/USAN/INN); 2-butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4.4]non-1-en-4-one; 8-butyl-7-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[4.4]non-8-en-6-one; TL8000875; SMR000466306; KBioGR_001603; HMS1922J05; 2-n-butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one; 2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one; BIDD:GT0347; 2-butyl-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1,3-diaza-spiro[; D00523; SR 47436; CPD000466306; BMS 186295; C081309; NCGC00095122-03; STK645362; 138402-11-6; C07469; LS-60064; KBio3_001907; CHEMBL1513; irbesartan; Irbesartan [USAN:INN]; Irbetan; Spectrum4_001122; BMS Brand of Irbesartan; MLS000759408; KBio2_004799; BMS-186295; Spectrum2_001675
Trade NameAprovel; Karvea; Avapro; Avalide
CompanyBristol-Myers Squibb
IndicationHypertension
[ICD9: 401   ICD10: I10, I11, I12, I13, I15]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11
-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14
H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)
InChIKeyYOSHYTLCDANDAN-UHFFFAOYSA-N
Canonical SMILESCCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5    
Therapeutic ClassAntihypertensive Agents
CAS NumberCAS 138402-11-6
FormulaC25H28N6O
PubChem Compound IDCID 3749.
PubChem Substance IDSID 9672.
ChEBI5959;
SuperDrug ATC IDC09CA04
SuperDrug CAS ID138402116;
TargetType-1 angiotensin II receptorAntagonist[2]
Ref 1New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22. To Reference
Ref 2Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543